Short Inflammatory Bowel Disease Questionnaire
Also known as: IBDQ-32, Short IBDQ
The Short Inflammatory Bowel Disease Questionnaire (IBDQ-32) is a validated patient-reported outcome measure designed to assess the impact of inflammatory bowel disease (IBD)—both ulcerative colitis and Crohn's disease—on health-related quality of life. Derived from the original 32-item IBDQ, this instrument comprises four domains: Bowel Symptoms, Systemic Symptoms, Social Function, and Emotional Function. The IBDQ-32 is responsive to treatment and is increasingly used in IBD clinical trials and practice.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
IBDQ-32 is indicated for patients with established IBD (UC or Crohn's disease) requiring baseline quality-of-life assessment and monitoring of treatment impact. It is used at initial assessment to understand the burden of IBD beyond disease activity indices. During active treatment (induction therapy, biologic escalation), IBDQ-32 is repeated at 8–12 weeks to quantify improvement in quality of life. In maintenance remission, IBDQ-32 is used to assess whether remission is accompanied by normal quality of life or residual functional impairment (suggesting need for additional interventions). IBDQ-32 is valuable in clinical trials comparing IBD therapies, where patient-reported outcomes complement objective disease activity measures.
Strengths & limitations
- Comprehensive quality-of-life assessment: Four subscales capture bowel-specific, systemic, social, and emotional dimensions, providing a holistic picture of IBD burden.
- Complements disease activity measures: IBDQ-32 captures functional and psychological impacts not quantified by Mayo Score, CDAI, or HBI; identifies patients in remission with poor quality of life.
- Responsive to treatment: IBDQ-32 improves significantly with biologic therapy, immunosuppressive agents, and surgical intervention; sensitive to clinical benefit.
- Validated in both UC and Crohn's: Single instrument applicable to both IBD types, enabling comparison across disease categories.
- No objective disease measure: IBDQ-32 quantifies quality-of-life perception but does not measure disease activity (inflammation, endoscopic severity) independently; should be combined with objective measures.
- Recall bias: 2-week recall depends on patient memory; recent flares or remissions may disproportionately influence scores.
- Ceiling effects in remission: Many IBD patients in remission cluster near the upper end of IBDQ-32 (>6.0), limiting ability to detect further improvement.
- Does not account for long-term complications: IBDQ-32 assesses current symptoms but does not predict or quantify long-term risks (colorectal cancer, malabsorption, strictures).
Frequently asked
Can IBDQ-32 be used as a disease activity measure?
No. IBDQ-32 measures quality of life and functional impact, not disease activity. A patient with high IBDQ-32 (>6.0) may have active endoscopic disease; conversely, one with low IBDQ-32 may be in endoscopic remission but have residual symptoms or psychosocial distress. Always use objective disease activity measures (Mayo Score, CDAI, HBI, CRP, fecal calprotectin) alongside IBDQ-32.
How does IBDQ-32 differ from generic quality-of-life instruments like SF-36?
IBDQ-32 is disease-specific, capturing IBD-relevant symptoms and impacts (bowel function, systemic inflammation effects). SF-36 is generic and less sensitive to IBD-specific changes. For IBD assessment, IBDQ-32 is preferred due to superior responsiveness. SF-36 is valuable for comparing IBD with other chronic diseases (asthma, diabetes).
What if a patient has low IBDQ-32 despite objective remission?
This patient has 'objective remission with poor subjective quality of life'. Investigate: (1) residual symptoms not captured by objective measures (urgency, incomplete evacuation, bloating), (2) depression or anxiety, (3) unrealistic remission expectations, (4) sexual dysfunction or social isolation. Consider additional interventions: antidepressants, psychological support, patient education, or dietary optimization (low-FODMAP, Mediterranean diet).
How frequently should IBDQ-32 be measured?
At baseline (diagnosis or before therapy change), establish IBDQ-32. During active treatment (induction phase), measure every 4–8 weeks to monitor early response. In maintenance remission, measure every 6–12 months or if symptoms change. In clinical trials, IBDQ-32 is typically measured every 4–12 weeks depending on study duration.
Is IBDQ-32 affected by depression?
Yes. Depression is common in IBD and significantly reduces IBDQ-32 scores, particularly the Emotional Function subscale. Distinguishing IBD-related quality-of-life impairment from depression-related impairment is challenging. Screen for major depression (PHQ-9 ≥10); if present, treat depression concurrently with IBD management. Both conditions contribute to low IBDQ-32.
Sources
- Guyonnet, D., Chassany, O., Ducroc, R., Picard, C., Mouret, M., D'Haens, G., & Svartz, H. (2004). Effect of fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in France: A multicentre, randomized, double-blind, controlled trial. Alimentary Pharmacology & Therapeutics, 20(4), 459–465. link ↗
How to cite this page
ScholarGate. (2026, June 3). Short Inflammatory Bowel Disease Questionnaire. ScholarGate. https://scholargate.app/en/gastroenterology/ibdq-short
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Crohn's Disease Activity IndexGastroenterology↔ compare
- Harvey-Bradshaw IndexGastroenterology↔ compare
- Mayo ScoreGastroenterology↔ compare
- Simple Clinical Colitis Activity IndexGastroenterology↔ compare